Adicet Bio Inc To Discuss Recent Data-Cut Date From Phase 1 Study Call Transcript
Welcome to Adicet's specially scheduled Conference Call. This call is being recorded. At the end of the company's prepared remarks, we'll open the call for questions, and we'll provide specific instructions at that point.
I would now like to turn the call over to Anne Bowdidge. Please go ahead.
Good morning. Thank you for joining us. On the call today from Adicet are Chen Schor, President and CEO; Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer. In addition, we're pleased to have Dr. Sattva Neelapu, Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center joining us today.
Before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking statements that are made under the safe harbor provisions of the securities laws, including, but not limited to, expressed or implied statements regarding the potential safety, durability, tolerability and efficacy of ADI-001, future
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |